Last reviewed · How we verify
NCT06377241
ScentAware and OCT in MCI vs HC
trial testing ScentAware in Alzheimer Disease, Early Onset in 20 participants. Terminated before completion.
5 June 2024
Quick facts
| Lead sponsor | University of Wisconsin, Madison |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 15 April 2024 |
| Primary completion | 5 June 2024 |
| Estimated completion | 5 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ScentAware
- UPSIT
Conditions studied
- Alzheimer Disease, Early Onset — all drugs for Alzheimer Disease, Early Onset →
Sponsor
University of Wisconsin, Madison
Who can join
Adults 50 to 80, any sex, with Alzheimer Disease, Early Onset. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are: * Whether the test is as effective and reliable as the standard test * Whether there is a link between the results of the smell test and the structure of the back of the eye Participants will: * complete a short questionnaire * have pictures of the inside of their eyes taken * perform two smell tests
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06377241
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease, Early Onset
Currently open trials in the same condition.
- NCT06814730 — A Study to Assess THN391 in Subjects With Alzheimer's Disease · Phase 1 · recruiting
- NCT06688968 — Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease · NA · recruiting
- NCT06668610 — A Multifocal TDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia · NA · recruiting
- NCT06268886 — Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Partici · Phase 2 · active not recruiting
- NCT05983575 — A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease · Phase 3 · active not recruiting
Other University of Wisconsin, Madison trials
Trials by the same sponsor.
- NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
- NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
- NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
- NCT07470723 — The ORIGIN-FH Study · NA · recruiting
- NCT06975657 — Well-being Skills for Reentry · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06377241 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
- Last refreshed: 23 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06377241.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing